Anacetrapib

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Anacetrapib
Anacetrapib.svg
Names
IUPAC name
(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one
Other names
MK-0859
Identifiers
3D model (JSmol)
ChemSpider
KEGG
UNII
Properties
C30H25F10NO3
Molar mass 637.51 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YesYN ?)
Infobox references

Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort prevent cardiovascular disease.[1] In 2017 its development was abandoned by Merck.[2]

Evidence[edit]

A 2017 review found that while the medication improves cholesterol levels in the blood it does not decrease the risk of heart problems in those at high risk.[3]

See also[edit]

Other CETP inhibitors:

References[edit]

  1. ^ Gutstein DE, Krishna R, Johns D, et al. (2012). "Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction". Clinical Pharmacology & Therapeutics. 91 (1): 109–122. doi:10.1038/clpt.2011.271. 
  2. ^ "Merck says will not seek approval of cholesterol treatment". Reuters. 2017. Retrieved 18 October 2017. 
  3. ^ Filippatos, TD; Kei, A; Elisaf, MS (29 September 2017). "Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?". Diseases (Basel, Switzerland). 5 (4). doi:10.3390/diseases5040021. PMID 28961179. 

Further reading[edit]